Frederic Seifer, MD
Pulmonary Disease · Potsdam, NYNPI 1528013729
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Baxter Healthcare at 39.8% of the total. Reporting peaked in 2022 at $37,339 and has fallen 99.9% since, to $53 in 2025. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 415 payments — averaging $188.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$31K
- Advanced Respiratory, Inc$28K
- Inogen, Inc.$7K
- Philips North America LLC$6K
- GSK$2K
- AstraZeneca$1K
- plus $4K from 21 others
Across 20 payments — averaging $2885.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$20K
- Chiesi USA, Inc.$15K
- Insmed, Inc.$15K
- Novartis$7K
What the payments were for
- Consulting fees$35,11645%
- Speaking & faculty fees$32,28741%
- Travel & lodging$3,4454%
- Food & beverage$7,46410%
- Education$1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 18 | $31,228 |
| Advanced Respiratory, Inc | 47 | $28,407 |
| Inogen, Inc. | 3 | $6,917 |
| Philips North America LLC | 50 | $5,718 |
| GSK | 101 | $1,530 |
| AstraZeneca | 60 | $1,063 |
| Boehringer Ingelheim | 33 | $601 |
| Electromed, Inc. | 30 | $571 |
| ZOLL Medical Corporation | 1 | $555 |
| Sunovion Pharmaceuticals Inc. | 3 | $429 |
| Grifols USA, LLC | 22 | $397 |
| Sanofi | 11 | $343 |
| Mylan Specialty L.p. | 7 | $128 |
| Amgen | 5 | $103 |
| Regeneron Healthcare Solutions, Inc. | 5 | $98 |
| Insmed, Inc. | 5 | $82 |
| Fisher & Paykel Healthcare Inc | 1 | $40 |
| AbbVie | 2 | $37 |
| Circassia Inc. | 2 | $29 |
| Genentech USA, Inc. | 2 | $23 |
| Pharming Healthcare, Inc. | 1 | $23 |
| Pfizer | 1 | $21 |
| Abbott | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Monaghan Medical Corporation | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hillrom - Life 2000 Ventilation System$30,542
- The Vest System Model 105 Home Care$17,101
- Hillrom - Vest System Model 105 Home Care$16,089
- The Monarch Airway Clearance System$15,301
- Life 2000 Ventilation System$5,585
- INOGEN$5,567
- (8829) Respiratoriy Care Undiv$4,132
- The MetaNeb System$3,895
- Hillrom - MetaNeb System$3,383
- InogenOne$1,350
- US Und$127
- AREXVY$123
- inCourage$110
- SYMBICORT$107
- FASENRA$107
How this compares
$78,417 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 267 | $232,718 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 222 | $130,079 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 143 | $100,105 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 149 | $92,694 |
| Spiriva RespimatTiotropium Bromide | 115 | $77,778 |
| NucalaMepolizumab | 15 | $75,247 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 120 | $71,017 |
| Dupixent PenDupilumab | 17 | $63,787 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 45 | $22,252 |
| Incruse ElliptaUmeclidinium Bromide | 33 | $16,637 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $12,992 |
| Pirfenidone | 17 | $11,741 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 251 | $8,971 |
| Arnuity ElliptaFluticasone Furoate | 20 | $6,527 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $5,595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta, Breo Ellipta | $1,530 | $436,815501 claims |
| Boehringer IngelheimCombivent Respimat, Spiriva Respimat, Stiolto Respimat | $601 | $278,875457 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $1,063 | $127,952211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Potsdam
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
- Ali El AtatBrooklyn$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.